Vaccine Info

mRNA-1653 hMPV+PIV3 Vaccine

Authored by
Last reviewed
December 1, 2021
Fact checked by
Robert Carlson, MD

mRNA-1653 Vaccine Description

mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.

mRNA-1653 Vaccine Indication

mRNA-1653 is designed to protect against human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections. 

mRNA-1653 Vaccine News

November 4, 2021 - Moderna is enrolling seropositive pediatric participants (12-36 months of age) in the Phase 1 study of the hMPV/PIV3 study (mRNA-1653). The first cohort in this study is fully enrolled. 

September 17, 2020 - Moderna reported the First 10 pediatric patients dosed in Phase 1 study of hMPV/PIV3 vaccine (mRNA-1653). Sites have re-opened and are actively recruiting participants. Moderna owns worldwide commercial rights to mRNA-1653.

mRNA-1653 Vaccine Clinical Trials

Moderna has begun to recruit for Phase 1 Clinical Trial NCT04144348. 

Clinical Trial NCT03392389:  Phase 1 Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults. This study was completed on July 29, 2019.  No results have been posted.